Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
“Larry has provided significant expertise to the clinical team throughout the IGNITE phase 3 program for eravacycline, our lead antibiotic candidate, as well as in the early clinical development of the Company’s pipeline programs,” said
“I am excited to be taking on this leadership role at Tetraphase,” said Dr. Tsai. “I look forward to continuing to work with the rest of management to realize the full potential of eravacycline as a treatment option for serious, and often life-threatening, MDR gram-negative infections.”
Dr. Tsai joined the Company in 2014 as senior medical director and became vice president, clinical development in 2015. He has nearly 20 years of experience in healthcare and clinical development. Prior to joining Tetraphase, he was vice president of research and development, in addition to medical director, at Aeris Therapeutics. Dr. Tsai is also a practicing physician at Brigham and Women’s Hospital in
Dr. Tsai holds a Bachelor of Science in Biology from
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed enrollment of phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Source: Tetraphase Pharmaceuticals, Inc.